How Common Is Lactic Acidosis with Metformin?
Lactic acidosis occurs rarely with metformin, at about 4.3 cases per 100,000 patient-years based on postmarketing data.[1] This rate is similar to non-users, suggesting metformin does not substantially elevate overall risk in the general population.[2]
Who Is at Higher Risk?
Risk increases in patients with kidney impairment (eGFR below 30 mL/min/1.73 m²), where metformin accumulation can occur, or those with acute conditions like dehydration, sepsis, or heart failure that worsen acidosis.[1][3] Age over 65, liver disease, and excessive alcohol use also heighten vulnerability by impairing lactate clearance.[2] In these groups, incidence can rise to 1 in 1,000 or higher if unmonitored.[4]
What Causes It Mechanistically?
Metformin inhibits mitochondrial complex I, mildly raising lactate production, but this rarely leads to acidosis unless clearance is compromised by renal failure or hypoxia. Unlike older biguanides like phenformin (banned for high risk), metformin's safer profile stems from lower potency and better renal excretion.[1][5]
How Do Symptoms and Diagnosis Work?
Early signs include nausea, vomiting, abdominal pain, hyperventilation, and fatigue, progressing to muscle weakness, drowsiness, or coma. Diagnosis involves elevated lactate (>5 mmol/L) with pH below 7.35, often alongside high metformin levels.[3] Blood tests confirm anion gap metabolic acidosis.
What Should Doctors Do to Prevent It?
Guidelines recommend checking eGFR before starting and periodically; discontinue if below 30 mL/min or during acute illness like surgery or contrast dye use.[1][6] Hold metformin 48 hours before procedures risking kidney injury, resuming only after normal function returns.[3]
How Is Lactic Acidosis Treated?
Immediate steps include stopping metformin, IV fluids, bicarbonate for severe acidosis, and hemodialysis to remove metformin and correct lactate—effective in most cases with survival over 50% if caught early.[4][7] Delay worsens mortality.
Does Real-World Data Match the Hype?
Large studies like a UK cohort of 600,000 patients found no increased risk versus sulfonylureas (odds ratio 1.01), debunking outdated fears.[2] FDA black-box warning persists due to rare severe cases, but benefits for type 2 diabetes outweigh risks for most.[1]
Sources
[1]: FDA Metformin Label
[2]: Richy et al., Diabetes Care 2009
[3]: Kalantar-Zadeh et al., Am J Kidney Dis 2020
[4]: ECTR Registry Data
[5]: Bailey, Diabetes Obes Metab 2017
[6]: ADA Standards of Care 2023
[7]: Belle et al., Crit Care 2009